Jan 08,2024 TOP STORY

Dexcom Reports Preliminary, Unaudited Revenues and Announces Its New Sensor Stelo

Dexcom reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 to be at least $1.030 billion, an increase of 26% over the fourth quarter of 2022. U.S. revenue is expected to be approximately $765 million, representing growth of 26% over the fourth quarter of 2022. International revenue is expected to be approximately $265 million, an increase of 27% over the fourth quarter of 2022. For 2024, Dexcom currently anticipates total revenue of approximately $4.15 billion to $4.35 billion, representing expected organic growth of approximately 16% to 21% over 2023. The company also announced today that Stelo, its new glucose sensor designed specifically for people with type 2 diabetes who do not use insulin, was submitted to the FDA for review in Q4 2023. Stelo will offer 15-day sensor wear, a cash-pay option and a software experience tailored specifically for non-insulin users. The system is expected to launch in the U.S. in summer 2024. Dexcom will report its audited full fourth quarter and fiscal 2023 financial results on Thursday, February 8, 2024 after the close of market.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 20,2023

eddii, the Gamified Real-Time Diabetes Management App, Launches Nationwide

eddii marks a milestone with the announcement of its nationwide launch, bringing a gamified approach to diabetes management to all those living with the condition across the US. eddii functions as a smart, virtual health companion, delivering real-time feedback, support, and in-app rewards as a testament to healthy behavior. While initially prioritizing the well-being of children with diabetes and their families, eddii has set its sights on expanding into the adult market in the very near future. Since eddii's official API partnership was announced with Dexcom in June this year, the app has integrated with its users' real-time CGM readings, delivering updates on blood glucose levels as well.Those living with diabetes, wherever they are based in the US, can now install the eddii app from both the App Store for iOS users and Google Play for Android. eddii quickly amassed 16,000 sign-ups on the app's early access waitlist, while a phased rollout, starting in Oklahoma and gradually opening up across middle American states saw over 4,000 users within months.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 05,2024

Solera Health Expands Platform for Virtual Specialty Care Including Diabetes Care from 9amHealth

Solera Health, a technology company, has expanded its HALO Platform to include virtual specialty care. Its new HALO Platform — which was launched in October — helps customers manage all of their contracted point solutions in one place, whether they’re part of Solera’s network or their own contracted solutions. The new virtual specialty care offering on the Halo Platform is supported in partnership with 9amHealth, Vori Health and Oshi Health. San Diego, California-based 9amHealth offers cardiometabolic care for those with diabetes, obesity and co-conditions. Vori Health support those with back or joint pain, and Oshi Health offers a virtual digestive health center for gastrointestinal conditions. Other companies in Solera’s network that are on the Halo Platform include WeightWatchers for weight management, Sword Health for musculoskeletal conditions and Headspace for mental health. By offering virtual specialty care services on the Halo Platform, Solera ultimately aims to “serve as an integrator for a fractured, inefficient health system and experience — creating a new entry point into the care continuum at a lower cost,” said Ed Liebowitz, chief product officer of Solera Health.

COLLABORATION PARTNERSHIP

#institution

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jan 03,2024

ClouDr Group Limited Completes the Application for Registration as A Medical Device in China in Respect of ClouDT-01 for Diabetes Management

The board of directors of ClouDr Group Limited announced that the Group completed the application for registration as a medical device in the People's Republic of China in respect of ClouDT-01, a self-developed diabetes-related digital therapeutics product. By leveraging the Group's advanced digital medical artificial intelligence foundation model, comprehensive diabetes service management database, and extensive diabetes clinical experience, ClouDT-01 provides sensitivity analysis of related indicators for vital diseases, serving both clinical professionals and patients. It facilitates real-time, dynamic, and comprehensive diabetes management, and further benefits diabetes patients clinically.

PRODUCT

#dtx

View Analyst & Ambassador Comments
Go to original news
Dec 29,2023

PharmaSens submits insulin patch pump for FDA approval

PharmaSens announced today that it submitted an application for FDA approval for its Niia Essential insulin patch pump system. FDA submission follows the pump’s recent ISO 13485 certification for the Switzerland-based company. Niia Essential, the first of three patch pumps from PharmaSens, features a patient-centric design aimed at enhancing ease of use. PharmaSens designed its basal-bolus patch pump to combine the ease of an insulin pen with the advantages of a sophisticated pump. It features a 3 mL reservoir, offering extended usage periods and access to reimbursed patch pump therapy. PharmaSens CEO Marcel Both expects a favorable review from the FDA, with the company gearing up for a market launch. He also said the company has ongoing trade sale partnership discussions to ensure successful market entry. A sale would also allow the company to advance its product pipeline, which includes a closed-loop system and an integrated CGM sensor and pump.

PRODUCT

#insulin pump

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 04,2024

Smit.fit and Droobi Health Merge to Establish DroobiSmit: Dominating Digital Diabetes Solutions in MENA/GCC and South Asia

Smit.fit, a frontrunner in India's digital health landscape, and Droobi Health, a leading digital diabetes player in the Middle East from Doha, Qatar, have merged to form DroobiSmit with its headquarters in Singapore. This strategic move positions DroobiSmit as one of the leading digital diabetes solution providers across the MENA/GCC and South Asia regions, with support from key investors, including Qatar Development Bank (QDB), Qatar Science and Technology Park (QSTP), and M-venture (MVP) in Singapore. DroobiSmit leverages digital health services to enhance health, manage chronic conditions, and reduce care costs. Their offerings cater to prediabetes, diabetes, and hypertension, leveraging modern technology, personalised coaching, and data-driven insights. DroobiSmit is aiming to expand globally and drive healthcare innovation. Establishing a new office in Saudi Arabia marks a significant milestone and highlights opportunities in South Asia and the Middle East. The newly merged entity will expand its market share by leveraging AI, including predictive health, advanced monitoring, and personalized interventions, integrated with digital twin technology.

COLLABORATION MERGERS & ACQUISITION

#product & service

#coaching

View Analyst & Ambassador Comments
Go to original news
Jan 02,2024 TOP STORY

Fitterfly launches JEDi: A Leap Forward in AI-enabled Diabetes Interventions in India

Introducing JEDi — the new empathetic conversational coaching AI developed by the X-labs Innovation team at Fitterfly. JEDi aims to provide users with reliable and empathetic assistance in managing their nutrition, fitness, and overall well-being in a structured 28-day regimen, built as a game. It analyses user responses, health data, and preferences to offer customised advice and nudges towards healthier habits. "The JEDi architecture is hybrid with rule-based NLP on an Expert system foundation complemented with large language models (LLMs). It's connected to the Fitterfly knowledge base which powers our therapies," said Ammar Jagirdar, Head - X Labs at Fitterfly. JEDi is now available for use on the Fitterfly Metabolic Health app. The modules of JEDi will also be available as plug and play solutions for corporates to support employee wellness. It will offer seamless integration with healthcare systems, provide data-driven insights with better outcomes empowering patient self management and cost-efficient healthcare with an aim to help reduce the diabetes burden of India.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Jan 04,2024 TOP STORY

Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™

Eli Lilly and Company announced LillyDirect, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect offers a digital Pharmacy Solutions for select Lilly medicines powered by third party online pharmacy fulfillment services. Besides the digital pharmacy, LillyDirect also provides disease state and healthcare educational information to help empower and support patients on their care journeys; access to independent telehealth providers that could complement a patient's current primary care team or be an alternative to in-person care for certain conditions; and an independent search tool that allows a patient to find healthcare professionals near them if they prefer in-person care. "We launched LillyDirect with the hope that it will offer patients an innovative end-to-end experience to manage their health and access their medicines, so they can get back to living their lives." said Frank Cunningham, group vice president, global value and access at Lilly.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Jan 03,2024 TOP STORY

Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States

Better Therapeutics and Glooko announced a partnership to integrate Better Therapeutics’ AspyreRx digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform. This collaboration will enable healthcare providers in the United States who use the Glooko platform to identify suitable patients for AspyreRx, facilitate prescriptions, and track patients throughout their treatment. AspyreRx will be accessible on the Glooko healthcare provider (HCP) platform in the U.S. as a new treatment option. Additionally, by leveraging Glooko’s 'precision engagement' functionality, patients who are suitable candidates for AspyreRx will be flagged for healthcare providers. Frank Karbe, CEO of Better Therapeutics, said, “Glooko is an ideal partner for us to support the adoption of AspyreRx, given the extensive overlap between providers using the Glooko platform and those we have identified as early adopters for AspyreRx. Glooko’s precision engagement has the potential to accelerate access to AspyreRx for patients who may benefit from this innovative new treatment.”

COLLABORATION PARTNERSHIP

#connected device

#dtx

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES